Zydus' Desidustat Enters Pivotal Phase III Trial for Sickle Cell Disease in India

Zydus Lifesciences has secured a critical green light from India's top drug regulator, the DCGI, to kick off a Phase III clinical trial for its oral drug Desidustat in patients battling Sickle Cell Disease (SCD). This 203-day study, a major step toward potentially transforming treatment for millions in India, will evaluate the drug's safety and effectiveness in combating anemia, a hallmark of SCD, and is being conducted in close collaboration with the Indian Council of Medical Research (ICMR). The move comes after promising Phase II results and holds immense significance for a country grappling with one of the world's highest burdens of this genetic blood disorder. India faces a daunting public health challenge with nearly 20 million people affected by SCD, primarily in tribal communities, and approximately 50,000 children born with the condition annually. Current treatments like hydroxyurea and regular blood transfusions offer limited and often inconsistent relief, with significant accessibility and risk issues. Desidustat, an HIF-PH inhibitor, works by mimicking the body's natural response to low oxygen, aiming to boost red blood cell production more physiologically than existing injectable therapies, and has already received Orphan Drug Designation from the US FDA for SCD. This trial is perfectly timed with India's ambitious National Sickle Cell Anaemia Elimination Mission, which aims to eradicate the disease as a public health concern by 2047. If successful, Desidustat could offer a much-needed, accessible oral treatment option, complementing the mission's extensive screening and awareness efforts that have already identified millions of carriers and patients. The results of this large-scale, multi-center study will be keenly watched, as they could pave the way for a new era of SCD management in India and beyond.